Dr. Michael Hayden

2011 Killam Prize (Health Sciences)

University of British Columbia

Author of over 750 peer-reviewed publications and invited submissions (h-index of 100), Dr. Hayden focuses his research primarily on genetic diseases, including genetics of lipoprotein disorders, Huntington disease, predictive and personalized medicine. Dr. Hayden and his research group have identified 10 disease-causing genes which includes the identification of the major gene underlying high-density lipoprotein (HDL) in humans. This gene, known as ABCA1, has major implications for atherosclerosis and diabetes. Dr. Hayden also identified the first mutations underlying Lipoprotein Lipase (LPL) Deficiency and developed gene therapy approaches to treat this condition. He is also co-leader of the Canadian Pharmacogenomics Network for Drug Safety project, a BC-led Genome Canada-funded, national strategy to prevent adverse drug reactions. He is the most cited author in the world for ABCA1 and Huntington Disease.

What does it mean to be a Killam Laureate?
I feel very fortunate to be honoured in this way. The pursuit of science is the crucial step to solve human biological problems.  The discoveries made by Killam Laureates not only help our Canadian families but are felt worldwide. I am proud to be in the company of these many outstanding researchers.

How has Killam funding been of benefit to you?
This award has benefitted my trainees who continue to prosper and innovate.

Why did you choose to work with the University of British Columbia?
The University of British Columbia (UBC) is one of the world’s foremost universities. UBC provides a very nurturing atmosphere and promotes excellence and innovation. The research environment at UBC is outstanding.


Scroll to Top